Focused On-demand Library for Homeobox protein Meis2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O14770

UPID:
MEIS2_HUMAN

ALTERNATIVE NAMES:
Meis1-related protein 1

ALTERNATIVE UPACC:
O14770; A6NJI5; A8MWD5; B3KP98; B3KPQ6; Q96DI2; Q96KI4; Q96KI5; Q9NRS1; Q9NRS2; Q9NRS3

BACKGROUND:
The Homeobox protein Meis2, known for its alternative name Meis1-related protein 1, is integral to transcriptional regulation, engaging in complex interactions with HOX, PBX proteins, and DNA. It is essential for various biological processes, including the transcriptional activation of genes involved in pancreatic function, midbrain development, and myeloid differentiation.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in the disease 'Cleft palate, cardiac defects, and impaired intellectual development', Meis2 represents a significant target for drug discovery. Understanding the role of Homeobox protein Meis2 could open doors to potential therapeutic strategies, offering hope for patients suffering from related congenital malformations and developmental delays.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.